86780-90-7
基本信息
阿雷地平對照品
阿雷地平標準品
2,6-二甲基-4-(2-硝基苯基)-1,4-二氫-3,5-吡啶二羧酸甲基2-氧丙基酯
2,6-二甲基-4-(2-硝基苯基)-1,4-二氫-3,5-吡啶二羧酸 3-甲基 2-氧代丙基酯
3-甲基 5-(2-氧丙基)2,6-二甲基-4-(2-硝基苯基)-1,4-二氫吡啶-3,5-二羧酸
MPC-1304
ARANIDIPINE
Asanidipine
Aranidipine MPC1304
ARANIDIPINE USP/EP/BP
ARANIDIPINE MPC1304
MPC-1304
MPC 1304
Calcium Channel,inhibit,MPC 1304,Inhibitor,MPC-1304,Aranidipine,Ca channels,Ca2+ channels
3-Methyl 5-(2-oxopropyl) 2,6-diMethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
2,6-Dimethyl-4-(2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid methyl 2-oxopropyl ester
物理化學性質
安全數(shù)據(jù)
常見問題列表
Ca 2+ Channel
Aranidipine (MPC-1304) is a new Ca 2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in B max values for specific [ 3 H](+)-PN 200-110 binding to myocardial membranes compared to the control values. The B max values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The B max values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The K d values for myocardial [ 3 H](+)-PN 200-110 binding are unaltered by oral administration of Aranidipine.